Advertise on podcast: Translating Proteomics

Host Parag Mallick chats with Professor Afshin Beheshti who is a Professor of Surgery, Director of the Center for Space Biomedicine, and Associate Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. In addition, Professor Beheshti has a visiting researcher appointment at the Broad Institute of MIT and Harvard and is president of two non-profits – the COVID-19 International Research Team and Kwaai. The latter aims to democratize access to artificial intelligence through the design, construction, and maintenance of a free personal AI called Kwaai. Professor Beheshti’s research covers a range of topics focused on how circulating mirco RNAs and mitochondria impact health, but this conversation focuses primarily on Professor Beheshti’s work advancing our understanding of how spaceflight impacts biology. We cover: How research on spaceflight and biology is doneGaps that remain in our understanding of spaceflight and biologyOmics studies of spaceflight and biologyHow studying spaceflight and biology enhances our understanding of human health more broadly ResourcesTrivedi Institute for Space and Global Biomedicine New Institute at the University of Pittsburgh focused on “advancing human health through space-driven innovation” NASA Open Science Data Repository "Provides open access to biological and physical science datasets from spaceflight and ground studies, enabling data reuse for discovery and innovation." Camera et al., 2024. Agining and putative frailty biomarkers are altered by spaceflight Study on molecular biomarkers and frailty phenotypes in space Overbey et al., 2024. The Space Omics and Medical Atlas (SOMA) and international astronaut biobank An “integrated data and sample repository for clinical, cellular, and multi-omic research profiles” from a variety of space missionsSpace Omics and Medical Atlas (SOMA) website Corti et al., 2024. To boldly go where no microRNAs have gone before: spaceflight impact on risk for small-for-gestational-age infants Explores how miRNA signatures of “small-for-gestational-age” are impacted by the space environment Beheshti et al., 2013. Age and space irradiation modulate tumor progression: implications for carcinogenesis risk Some of Professor Beheshti’s early...

On this episode of Translating Proteomics, Parag and Andreas share their reflections on proteomics developments in 2025 largely inspired by their observations at the World HUPO 2025 conference in Toronto. Whether you agree, disagree, or simply want to share some of your own observations on proteomics, please post your thoughts in the comments. We look forward to even more exciting developments in 2026! Chapters00:00 - 00:35 – Intro 00:36 – 07:00 - Increased focus on applications of proteomics and less on method development Learn more about One Health from our conversation with Professor Jennifer Geddes-McAlister https://youtu.be/JFwvTdkb5bw 07:01 – 12:47 - Increase in people talking about the importance of proteoforms Learn more about proteoforms in our episode featuring proteoform pioneer Professor Neil Kelleher https://youtu.be/3pPuxVrMxpw 12:47 – 17:26 - An increase in multiomics studies 17:27 – 20:03 - A shift to larger scale proteomics studies For a great example of a multi-platform comparison study, check out Kirsher et al., 2025 https://www.nature.com/articles/s42004-025-01665-1 20:03 – 25:07 - Increased integration of AI into proteomics workflows For an example of how proteomics workflows can be modified with multiomic data, check out Suhre et al., 2025 https://www.nature.com/articles/s41588-025-02413-w 25:08 – 30:05 – Recognition of the need to assess quality across proteomics workflows 30:06 – 32:19 – Less of a focus on spatial proteomics this year than in past years 32:20 – 35: 13 - Parag and Andreas share their predictions for 2026 35:14 – End – Outro

On this episode of Translating Proteomics, Parag speaks with Professor Jennifer Geddes-McAlister from the University of Guelph. Professor Geddes-McAlister is an expert at using proteomics to study host-microbe interactions from a systems biology perspective. Her exciting work spans studies of pathogenic fungi all the way to engineering plants to produce pharmaceutics (so-called “molecular pharming"). On top of all that, Professor Geddes-McAlister also founded “Moms in Proteomics” to support and encourage an intentional focus on the inherently unique physical, emotional, and biological commitments of Mothers, and the ensuing balance required to excel within the diverse STEM fields encompassing Mass-Spectrometry-based proteomics. Dive into this episode to: Learn why it’s critical to study hosts, pathogens, and molecular pharming from a systems point of viewDiscover what Professor Geddes-McAlister is excited about for the upcoming Human Proteome Organization (HUPO) conferenceFind out what “Moms in Proteomics” has planned for HUPO Chapters00:00 - Intro 01:39 - Professor Geddes-McAlister's initial interest in host-microbe interactions 06:13 - Why it's important to study host-microbe interactions 08:10 - Pathogens vs helpful microbes 10:06 - Thinking about microbes through the lens of "One Health" 14:34 - Why Professor Geddes-McAlister works primarily in proteomics as opposed to other omes 19:44 - Professor Geddes-McAlister's favorite thing that she's learned from the proteome and couldn't learn from the other omes 24:56 - Molecular pharming 29:35 - The need for accessibility in proteomics 34:09 - The need for all-in-one workflows in proteomics 36:08 - HUPO 2025 39:56 - Moms in Proteomics 42:36 - The future of proteomics 43:59 - Outro ResourcesGeddes et al., 2015. Secretome profiling of Cryptococcus neoformans reveals regulation of a subset of virulence-associated proteins and potential biomarkers by protein kinase A https://pubmed.ncbi.nlm.nih.gov/26453029/ Some of Professor Geddes-McAlister’s early work using proteomics to study pathogenic fungi Prudhomme et al., 2024. Bacterial growth-mediated systems remodelling of Nicotiana benthamiana defines unique signatures of target protein production in molecular pharming https://onlinelibrary.wiley.com/doi/10.1111/pbi.14342 Researchers from Professor Geddes-McAlister’s lab use multiomic techniques to discover factors impacting the production of a pharmaceutical in an engineered plant Woods et al., 2023. A One Health approach to overcoming fungal disease and antifungal resistance https://wires.onlinelibrary.wiley.com/doi/full/10.1002/wsbm.1610 Review on the importance of incorporating “One Health” principals into efforts to fight pathogenic fungi Moms in Proteomics website https://momsinproteomics.ca Learn all about the Moms in Proteomics initiative and its international community

On this episode of Translating Proteomics, Parag, Andreas, and special guest Don Kirkpatrick answer questions submitted by the Translating Proteomics community. They cover: Needs in plasma proteomicsHow proteomics impacts drug development – with special guest Don Kirkpatrick, Ph.D.!How lifestyle impacts the proteomeHow the Nautilus Proteome Analysis Platform is impacting tau and Alzheimer’s disease research ReferencesShome et al., 2022 - Serum autoantibodyome reveals that healthy individuals share common autoantibodies https://www.sciencedirect.com/science/article/pii/S2211124722006489 LaBaer Lab paper investigating autoantibody levels in plasma and their relationship to health. Sylman et al., 2018 - A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients https://www.nature.com/articles/s41598-018-25019-1 Mallick lab paper investigating temporal changes in platelets and their associations with cancer biology. Krönke et al., 2014 - Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells https://www.science.org/doi/10.1126/science.1244851 Seminal paper describing selective protein degradation caused by lenalidomide. Fink and Ebert 2015 - The novel mechanism of lenalidomide activity https://ashpublications.org/blood/article/126/21/2366/34644/The-novel-mechanism-of-lenalidomide-activity Review of research elucidating the mechanisms of lenalidomide activity Ndoja et al., 2025 - COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway https://www.mdpi.com/2073-4409/14/13/975 Describe links between kinase inhibitor vemurafenib and changes in ETV transcription factor degradation Song et al., 2022 - RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy https://aacrjournals.org/cancerdiscovery/article/12/1/204/675622/RTK-Dependent-Inducible-Degradation-of-Mutant-PI3K Use proteomics to discover that inavolisib acts through selective degradation of mutant PI3Kα Canon et al., 2019 - The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity https://www.nature.com/articles/s41586-019-1694-1 Covers the development of an inhibitor of KRAS mutant KRAS (G12C). Schneider et al., 2024 - Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axis https://www.nature.com/articles/s42255-024-01108-6 Review on the gut-brain axis Webpage for Johanna Lampe’s Lab at Fred Hutch Cancer Center a href="https://www.fredhutch.org/en/faculty-lab-directory/lampe-johanna.html" rel="noopener noreferrer"...

On this episode of Translating Proteomics, host Parag Mallick discusses spatial proteomics with special guest Fiona Ginty Ph.D. Fiona is a Senior Principal Scientist in Precision Diagnostics at the GE Healthcare Technology & Innovation Center. She is a leader in the development of spatial proteomics technologies and their application in precision diagnostics and medicine. Their discussion covers: ·      How Fiona began working in spatial proteomics ·      Why spatial biology is important ·      What the future holds for spatial biology Chapters:00:00 – Introduction 01:54 – Fiona’s journey to biology 05:26 – Fiona’s transition to tool development 07:20 – Working at GE Research 11:26 – Identifying the importance of spatial biology 14:43 – How Cell DIVETM works 18:25 – The importance of single cell 23:01 - When Fiona realized the technology worked 28:04 – Spatial biology projects Fiona is excited about 30:08 – Fiona’s role in HuBMAP 36:50 – Learnings from HuBMAP so far 38:35 – The future of spatial proteomics in the clinic 46:56 – Current limits on spatial proteomics 49:56 – Current and future uses of AI in spatial proteomics 53:30 – The most exciting thing Fiona learned in her spatial proteomics journey 56:08 – Outro Resources:Method of the Year 2024: Spatial Proteomics Paper covering the spatial proteomics technology Fiona worked on at GE Healthcare Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue HubMAP – Human BioMolecular Atlas Program Human Tumor Atlas Network Cell DIVE Multiplex Imaging Solution Papers discussing what makes colorectal cancer cells undergo apoptosis in response to chemotherapy An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolutionIntegrated multiplex analysis of cell death regulators in stage II colorectal cancer suggests patients with ‘persister’ cell profiles fail to benefit from adjuvant chemotherapy Paper discussing how the distance between tumor cells and cytotoxic t-cells correlates to caspase level Spatial effects of infiltrating T cells on neighbouring cancer cells and prognosis in stage III CRC patients - Azimi - 2024 - The Journal of Pathology - Wiley Online Library Paper showing it takes 3 hits from cytotoxic...

On this special episode of Translating Proteomics, Parag and Andreas break down the basics of proteomics — perfect for anyone with a background in molecular biology looking to get started in the field. Seasoned experts: We hope you can share this episode as a teaching tool or to inspire others to explore proteomics. Parag and Andreas cover the following questions in the episode, and links to additional Nautilus resources can be found below each question. What is proteomics? Blog post – What is proteomics? Techniques, applications, and methods What are key questions proteomics can answer? Blog category – Applications of proteomics Why is it important to measure the proteome? FAQ on the Nautilus Resources pageBlog post – Genomics vs. proteomics: Two complementary perspectives on life What can and can't you do with proteomics? Translating Proteomics episode – Plasma Proteomics: The Dream and the NightmareLearn how the Nautilus Platform is designed to enable comprehensive broadscale proteomics and targeted proteoform studies What are key proteomics methods and techniques? Blog series – Traditional protein analysis methodsBlog series – Next-generation proteomics technologies What are the major pitfalls when doing proteomics? What are the challenges in proteomic data analysis? Translating Proteomics episode – Biology in Space and TimeBlog post – What is multiomics? What are people excited about in proteomics? Translating Proteomics episode – Poised for a Proteomics BreakthroughTranslating Proteomics episode - US HUPO 2025 – Key Takeaways, Trends, and Future Directions for ProteomicsTranslating Proteomics episode – a href="https://www.nautilus.bio/blog/translating-proteomics-episode-10-protein-function-201-with-kathryn-lilley/" rel="noopener noreferrer"...

If you listened to our episode focused on science communication featuring proteomics leaders Ben Orsburn Ph.D. and Ben Neely Ph.D., then you've already heard about their excellent podcast, The Proteomics Show. On The Proteomics Show, they interview researchers in the proteomics community to learn about their motivations, their backstories, and their work. Today, we're sharing an episode of The Proteomics Show where the Bens interview Translating Proteomics host Parag Mallick. Check it out to learn about Parag's journey to proteomics, his efforts advocating for open data sharing, and his work as a professional magician. After listening, be sure to check out more episodes of The Proteomics Show on their feed where you'll find over 70 interviews with many, many interesting people in the proteomics community. Find their feed here: https://us-hupo.org/Podcasts

On this episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer discuss their recent experience at the 2025 US Human Proteome Organization conference or US HUPO. Their conversation covers: ·      The rising use of multiple proteomics platforms ·      Advances in multiomics And ·      What they hope to see at the next US HUPO Chapters: 00:00 – Introduction 01:47 – Things Parag and Andreas were most excited about going into US HUPO 06:19 - Trends Parag observed at US HUPO ·      A bifurcation between studies that focused on measuring many proteins and those that focused on a specific biological process ·      People increasingly using multiomics to wholistically understanding biology as opposed to a means of comparing the different omes ·      A shift to researchers using multiple proteomics platforms 11:44 – The rising prominence of proteoforms at US HUPO 15:50 – The future of proteomics as informed by US HUPO 18:06 – What Parag and Andreas hope to see at the next US HUPO 19:57 - Outro

On this episode of Translating Proteomics, host Parag Mallick speaks with special guests doctors Ben Neely and Ben Orsburn, leaders in the proteomics community and hosts of “The Proteomics Show” podcast. Their insightful conversation focuses on the role of communication in proteomics and covers: ·      Impactful things they’ve learned while hosting The Proteomics Show ·      How their communication efforts have changed their research ·      Barriers to proteomics becoming more popular in the life sciences and in the broader public Chapters:00:00 – 03:04 – Intro 03:04 – 07:23 – Why the Bens created "The Proteomics Show" 07:23 – 10:42 – Ways the proteomics show has impacted the Bens’ research 10:42 – 16:44 – Every scientist is interesting! 16:44 – 20:36 – Ways the Bens' communication efforts have changed their research 20:36 – 25:08 – Trends in proteomics 25:08 – 35:34 – Barriers to communication between the proteomics community and others in the life science 34:34-48:34 - Barriers to communication between the proteomics community and the broader public 48:34 - End - Outro ResourcesThe Proteomics Show - Ben Neely and Ben Orsburn host this podcast sponsored by the Human Proteomics Organization. On it, they interview proteomics researchers in a “fireside chat” format. Their conversations cover not just the latest research, but also their guests’ motivations, hobbies, and histories. Definitely check it out!News in Proteomics Research - Ben Orsburn's blog on the latest developments in proteomics.Proteomics, the next truly massive investment opportunity - Forbes article on the potential of proteomics.The Magic School Bus Rides Again - Recently rebooted version of The Magic School Bus. Will we see an episode featuring proteomics?

On this episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer discuss the many ways proteomics can impact our interactions with food. Some of the topics they touch upon in this wide-ranging conversation include: ·      Proteomics and food quality ·      Proteomics and food safety ·      Developing new kinds of food with proteomics Chapters00:00 – 01:23 – Introduction 01:23 – 03:27 – Proteomics and alcohol fermentation 03:27 – 05:24 – Food properties and their relationship with molecular composition 05:24 – 07: 42 – How can we use proteoforms to improve food quality? 07:42 – 11:49 – Proteomics to aid plant and animal breeding 11:49 – 14:35 – Proteomics, Food Safety, and Food Security 14:35 – 17:05 – Proteomics and food authenticity 17:05 – 20:36 – Proteomics and terroir 20:36 – 22:48 – Proteomics, the microbiome, and health 22:48 – 24:29 – A fun party trick 24:29 – 30:24 – Creating new foods and flavors 30:24 – 34:33 – Designing food for space 34:33 – End – Outro ResourcesThe post-translational modification landscape of commercial beers (Kerr et al. 2021) ·      Paper looking at the ways post-translational modification differ between different beers and how protein content relates to the properties of foam Heat shock and structural proteins associated with meat tenderness in Nellore beef cattle, a Bos indicus breed (Carvalho et al. 2024) ·      Paper looking at the relationship between proteins and meat tenderness Comprehensive proteome analysis of bread dicphering the allergenic potential of bread wheat, spelt and rye (Zimmermann et al. 2021) ·      Research measuring the levels of allergens in different kinds of bread Differential proteomic analysis by SWATH-MS unravels the most dominant mechanisms underlying yeast adaptation to non-optimal temperatures under anaerobic conditions ·      Study using proteomics to reveal how yeast adapt to growth at different temperatures

On this episode of Translating Proteomics, co-hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss the reproducibility crisis in biology and specifically focus on how we can enhance reproducibility in computational proteomics. Key topics they cover include: •               What the reproducibility crisis is •               Factors that make it difficult to replicate multiomics research •               Steps we can take to make biology research more reproducible Chapters  00:00 – 01:20 – Introduction 01:20– 03:10 – What is reproducibility in research and why is it important? 03:10 – 05:42 – Recent work from the Mallick Lab focused on computational proteomics reproducibility 05:42 – 09:32 – Ways to help improve reproducibility in computational proteomics – More detailed documentation, moving beyond papers as our main form of documentation, and ensuring computational workflows are available, 09:32 – 11:30 – Why Parag got interested reproducibility – Attempts to build AI layers on top of current workflows 11:30 – 14:00 – The need to create repositories of analytical workflows codified in a structured way that AI can learn from 14:00 – 15:24 – A role for dedicated data curators 15:24 – 18:31 – Moving beyond the idea of study endpoints and recognizing data as part of a larger whole 18:31 – 21:32 – How does AI fit into the continuous analysis and incorporation of new datasets 21:32 – 23:36 – The role of AI in helping researchers design experiments 23:36 – 27:25 – Three things we can do today to increase the reproducibility of computational proteomics experiments: ·      Be clear about the stated hypothesis ·      Document analyses through workflow engines and containerized workflows ·      Advocate for support for funding for reproducibility and reproducibility tools 27:25 – End – Outro Resources Parag’s Gilbert S. Omenn Computational Proteomics Award Lecture o   In this lecture, Parag describes his vision for a more reproducible future in proteomics Nature Special on “Challenges in irreproducible research” o   A list of articles and perspective pieces discussing the “reproducibility crisis” in research Why Most Published Research Findings Are False (Ioannidis 2005) o   Article outlining many of the issues that make it difficult to reproduce research findings Reproducibility Project: Cancer Biology o   eLife initiative investigating reproducibility in preclinical cancer research Center for Open Science Preregistration Initiative o   Resources for preregistering a hypothesis as part of a study National Institute of Standards and Technology (NIST) o   US government agency that aims to...

On this episode of Translating Proteomics, co-hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss how clinical researchers can leverage proteomics for drug development. Some of the themes covered in this episode include: ·      Proteomics and pre-clinical models ·      How proteomics can drive patient selection ·      Choosing the right end points in clinical trials Chapters 00:00 – 01:06 – Introduction 01:06 – 06:51 – Proteomics in pre-clinical studies 06:51 – 11:40 – The importance of choosing the right model for preclinical work 11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials 17:10 – 19:29 – Proteomics tools in patient selection 19:29 – 24:33 – Useful information that we get from proteomics that we can’t get from genomics or transcriptomics 24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy 28:14 – 29:19 - Understanding why clinical trials fail 29:19 – End - Outro   Resources The National Cancer Institute’s webpage covering how clinical trials workPreprint on the miBrain model - An example of a new in vitro brain modelGeary et al., 2021 - Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical TrialsWasko et al., 2024 - Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerThe NCI-MATCH trail: Lessons for precision oncology – Report on a large-scale trial using genomic biomarkers to match cancer patients to treatmentsTumour-selective activity of RAS-GTP inhibition in pancreatic cancer – Study using proteomics to understand mechanisms of resistance to a cancer drug

On this special, year-end episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer discuss three of their favorite proteomics publications from 2024. They'll cover one paper in each of the following topic areas: Proteomics in pre-clinical researchProteomics in basic researchTechnology development in proteomics Synopses of each of the papers can be found below and you can find many more insights in the podcast. Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomicsIn this work from Professor Bernhard Kuster’s Lab at the Technical University of Munich, researchers assess protein abundance changes that result from treating Jurkat acute T cell leukemia cells with 144 drugs over five drug doses. The researchers use their proteomic data to generate millions of dose response curves for the thousands of proteins measured and discover that the drugs impact many more proteins and pathways than those identified as drug targets. In addition, they checked how 7 of the drug treatments impacted the transcriptome and found there was often discordance between impacts at the mRNA level and the protein level. This works highlights the many ways drugs can impact biological systems and suggests that similar studies will help researchers understand the effects of drug treatments and may even aid in the development of more effective or more specific therapies. Find the publication here. Natural proteome diversity links aneuploidy tolerance to protein turnoverAs we discussed on a previous episode of Translating Proteomics, genome alterations often fail to faithfully propagate to the proteome. In this work, researchers from the labs of Professor Judith Berman at Tel Aviv University and Professor Markus Ralser at the Charité - Universitätsmedizin Berlin, investigate the means through which yeast strains adapt to chromosome gains or losses (aneuploidy). They assess the concordance between changes in mRNA and protein expression in aneuploid yeast that were either found in nature or generated in the lab. The researchers observed dosage compensation, a tendency to return to expression levels associated with normal chromosome numbers, for both mRNAs and proteins expressed on aneuploid chromosomes. However, dosage compensation was much stronger at the protein level than the mRNA level and even stronger at the protein level in naturally aneuploid strains compared to lab-generated strains. This work suggests that multiomics efforts are necessary to determine the effects of genomic alterations. In addition, the authors find that protein degradation, as observed through increased ubiquitination, increased turnover of proteins encoded in aneuploid chromosomes, and the up regulation of the proteasome complex, is a key means of dosage compensation. Finally, because the naturally aneuploid strains achieved a higher level of dosage compensation than the lab-generated strains, the authors suggest there has been selection for natural aneuploid strains that down-regulate proteins causing detrimental effects. a...

Parag Mallick discusses the role of AI and machine learning in biotech with special guests Vijay Pande from Andreessen Horowitz and Matt McIlwain from Madrona Venture Group. Their fascinating conversation covers: Advances that have enabled biotech to make use of AI and machine learningHow founders are applying AI and machine learning in biotechThe future of AI and machine learning in biotech Chapters 00:00 - Introduction 04:37 - How did Vijay and Matt get into AI and ML 07:33 - The importance of structured data, advances in compute, and algorithmic advances in driving the boom in machine learning 18:44 - The Intersection of AI and biology 21:57 - The evolution of biological models 31:55 - The Complexity of biological data 39:42 - Ways founders and biotech startups are using AI 43:25 - Favorite/Impactful applications of AI/ML 47:00 - AI for experimental design 50:13 - The future of AI in bio/health Resources Learn more about Matt McIlwainLearn more about Vijay PandeFolding at HomeLearn about various types of machine learning on IBM's websiteLearn about autoencoders on IBM's websiteLearn more about transformers on NVIDIA's blogTranslating Proteomics Episode 6 - The Future of AI in Biomedicine

Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to [email protected]! On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer’s research with special guest and Curie Bio Drug Maker in Residence, Sarah DeVos Ph.D. Their conversation focuses on: The impact of molecular diagnostics on Alzheimer’s researchRecent Alzheimer’s drug approvalsThe future of Alzheimer’s research *Small edit on Sarah's background - She did her graduate work at Washington University in St. Louis and a Postdoc at Massachusetts General Hospital* Chapters00:00 – Introduction 01:54 – Why Sarah began studying Alzheimer’s 03:39 – Current tools and needs for future Alzheimer’s diagnostics 09:52 – Recent drug approvals in the Alzheimer’s space and their relationship to diagnostics 14:26 – Is it possible to develop biomarkers that detect Alzheimer’s at its earliest stages? 16:36 – What is limiting the development of new Alzheimer’s biomarkers? 17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer’s 19:33 – The genetics of Alzheimer’s 22:19 – Novel approaches to identifying and understanding Alzheimer’s pathology  25:54 – Where can proteomics advance Alzheimer’s research? 31:25 – The role of proteomics in Alzheimer’s animal models 34:33 – Sarah’s hopes for the next 10 years of Alzheimer’s research 41:39 - Outro ResourcesDominant Inherited Alzheimer’s Network (DIAN) trials research updates o   In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer’s disease. Amyloid plaque reducing clinical trials: o   Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease (Haeberlein et al. 2022) o   Donanemab in Early Symptomatic Alzheimer Disease - The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (Sims et al. 2023) o   Lecanemab in Early Alzheimer’s Disease (Van Duck et al. 2022) Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Car (Palmqvist et al. 2024) o   Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer’s disease Resurrecting the Mysteries of Big Tau (Fischer and Baas 2021) o   Review covering a potentially neuro-protective form of tau called “Big tau” Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience...